DE1770273A1 - New basic ketones - Google Patents
New basic ketonesInfo
- Publication number
- DE1770273A1 DE1770273A1 DE19681770273 DE1770273A DE1770273A1 DE 1770273 A1 DE1770273 A1 DE 1770273A1 DE 19681770273 DE19681770273 DE 19681770273 DE 1770273 A DE1770273 A DE 1770273A DE 1770273 A1 DE1770273 A1 DE 1770273A1
- Authority
- DE
- Germany
- Prior art keywords
- ethyl
- new basic
- general formula
- iso
- basic ketones
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000002576 ketones Chemical class 0.000 title claims description 6
- -1 hexamethyleneimine radical Chemical group 0.000 claims description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 7
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- IXQGCWUGDFDQMF-UHFFFAOYSA-N 2-Ethylphenol Chemical compound CCC1=CC=CC=C1O IXQGCWUGDFDQMF-UHFFFAOYSA-N 0.000 claims description 4
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical group CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 claims description 4
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 claims description 3
- KWHPWBXOLZTZMJ-UHFFFAOYSA-N 4-ethylpiperidine Chemical group CCC1CCNCC1 KWHPWBXOLZTZMJ-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 claims description 2
- 229940073735 4-hydroxy acetophenone Drugs 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- YZWKKMVJZFACSU-UHFFFAOYSA-N 1-bromopentane Chemical compound CCCCCBr YZWKKMVJZFACSU-UHFFFAOYSA-N 0.000 claims 1
- CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 claims 1
- 238000005727 Friedel-Crafts reaction Methods 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 206010002091 Anaesthesia Diseases 0.000 description 7
- 230000037005 anaesthesia Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 125000000468 ketone group Chemical group 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 4
- 229940035674 anesthetics Drugs 0.000 description 4
- 239000003193 general anesthetic agent Substances 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- PXWYZLWEKCMTEZ-UHFFFAOYSA-N 1-ethyl-2-nitrobenzene Chemical compound CCC1=CC=CC=C1[N+]([O-])=O PXWYZLWEKCMTEZ-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 229930194542 Keto Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 150000003840 hydrochlorides Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010002153 Anal fissure Diseases 0.000 description 2
- 208000016583 Anus disease Diseases 0.000 description 2
- 208000009531 Fissure in Ano Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 238000002692 epidural anesthesia Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- 125000006606 n-butoxy group Chemical group 0.000 description 2
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 2
- 125000006608 n-octyloxy group Chemical group 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- VERVERDPMMBDSS-UHFFFAOYSA-N (2-ethylphenyl) acetate Chemical compound CCC1=CC=CC=C1OC(C)=O VERVERDPMMBDSS-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001464016 Pedum Species 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- XXCBNHDMGIZPQF-UHFFFAOYSA-L bismuth(2+);5-carboxy-3-hydroxybenzene-1,2-diolate;hydrate Chemical compound O.OC1=CC(C(=O)O)=CC2=C1O[Bi]O2 XXCBNHDMGIZPQF-UHFFFAOYSA-L 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
Neue basische Ketone Die Erfindung betrifft neue basische Ketone der allgemeinen Formel worin R eine n-oder iso-Alkoxy-Gruppe der Kettenlänge C3-Cb, R1 einen Dibutylamin-, Piperidin-, Pyrrolidin-, 4-Äthylpiperidin-, Morpholin- oder Hexamethyleniminrest bedeutet.New basic ketones The invention relates to new basic ketones of the general formula where R is an n- or iso-alkoxy group of chain length C3-Cb, R1 is a dibutylamine, piperidine, pyrrolidine, 4-ethylpiperidine, morpholine or hexamethyleneimine radical.
Die erfindungsgemä#en Verbindungen zeichnen sich durch starke Änästhesierungswirkung aus.The compounds according to the invention are distinguished by a strong anesthetic effect the end.
Es sind bereits hochwirksame Anästhetika in Gestalt von 4-Alkoxy-ß-piperidinopropiophenonen bekannt (DDR-Patentschrift Nr. 268).There are already highly effective anesthetics in the form of 4-alkoxy-ß-piperidinopropiophenones known (GDR patent specification No. 268).
Substanzen dieser Reihe, angefangen mit der 4-Propoxy-Verbindung, besitzen eine sehr starke Anästhesierunswirkung sowohl in oberflächen- als auch in lokalanästhetischer Hinsicht. Die Propoxy-Verbindung wurde unter der Bezeichnung Propoxypiperoc ainumhydrochloricum in das DAB 7 aufgenommen und ist bereits seit 1952 im Handel.Substances of this series, starting with the 4-propoxy compound, have a very strong anesthetic effect both on the surface and on the surface in local anesthetic terms. The propoxy compound was under the name Propoxypiperoc ainumhydrochloricum included in the DAB 7 and has been on the market since 1952.
Die Substanzen der gekennzeichneten Reihe sind jedoch relativ toxisch, was allerdings bei ihrer Anwendung nicht sehr nachteilig ist, da bei der starken anästhetischen Wirksamkeit des Propoxypiperocainum-hydrochloricums, die #10-12fach so groß ist wie die von Cocain oder 4-Aminobenzoesäurediäthylaminoäthylester, nur sehr geringprozentige Lösungen notwendig sind.However, the substances in the marked series are relatively toxic, which, however, is not very disadvantageous in their application, since the strong one anesthetic effectiveness of Propoxypiperocainum hydrochloricums, the # 10-12fold is as large as that of cocaine or 4-aminobenzoic acid diethylaminoethyl ester, only very low percentage solutions are necessary.
Es wurde gefunden, daß durch Einführung einer Xthylgruppe in das Ringsystem in 3-Stellung zur Ketogruppe eine ganz wesentliche Toxizitätssenkung erreicht wird.It has been found that by introducing an ethyl group into the ring system in the 3-position to the keto group a very substantial reduction in toxicity is achieved.
Tabelle 1: Toxizität von ß-R1-3-Äthyl-4-alkoxypropiophenonhydrochloriden
Die in den nachstehenden Tabellen genannten Anästhesiestärken wurden nach Profft (E. Profft, Eröffnungs- und Vortragstagung Chem. Ges. DDR, Leipzig, Tagungsberichte 1954, Dtsch. Verlag der Wissenschaften Berlin, S. 134) mit Hilfe des Zungentestes wie folgt bestimmt: 0,5 ml der einprozentigen wässrigen Lösung der betreffenden Verbindung wurden 45 Sekunden auf der Zunge einwirken gelassen. Nach sofortigem dreimaligen Ausspülen des Mundes wurde das Anästhesieempfinden in Abhängigkeit von der Zeit festgestellt. Dabei bedeutet Anästhesiestärke 1 = schwach, 2 = mittel, 3 = stark, 4 = sehr stark.The anesthetic strengths given in the tables below were after Profft (E. Profft, opening and lecture conference Chem. Ges. DDR, Leipzig, Conference reports 1954, Dtsch. Verlag der Wissenschaften Berlin, p. 134) with help of the tongue test determined as follows: 0.5 ml of the one percent aqueous solution the compound in question was left to act on the tongue for 45 seconds. After immediately rinsing the mouth three times, the sensation of anesthesia became in Determined as a function of time. Anesthesia strength 1 = weak, 2 = medium, 3 = strong, 4 = very strong.
Tabelle 2: Anästhesie von ß-Piperidino-3-äthyl-4-alkoxypropiophenonhydrochloriden
Die erfindungsgemäßen neuen Verbindungen der allgemeinen Formel (I) werden auf folgendem Weg erhalten: 2-Athylpilenol, gewonnen aus dem Abfallprodukt der Chloramphenicolsynthese, dem o-Nitroäthylbenzol, wird in Gestalt des Acetats der Fries'schen Verschiebung unterworfen, die Hydroxygruppe veräthert und die 4-Alkoxy-3-äthylacetophenone nach Mannich in die en;tsprechenden Ketobasen übergeführt.The new compounds of the general formula (I) according to the invention are obtained in the following way: 2-Ethylpilenol, obtained from the waste product the chloramphenicol synthesis, the o-nitroethylbenzene, is in the form of the acetate subjected to the Friesian shift, the hydroxy group etherified and the 4-alkoxy-3-äthylacetophenone converted into the corresponding keto bases according to Mannich.
Ein wesentlicher Vorteil bei der Gewinnung der Wirkstoffe liegt darin, daß bei der Fries'schen Verschiebung kein Isomeres entsteht, sondern ausschließlich die Verbindung mit der Ketogruppe in 1-Stellung erhalten wird.A major advantage in obtaining the active ingredients is that that in the Friesian shift no isomer is produced, but exclusively the connection with the keto group in the 1-position is obtained.
Die einzelnen Verfahrensstufen sind in sehr guten Ausbeuten durchführbar.The individual process stages can be carried out in very good yields.
Man kann aber auch 2-thyl-phenylaIkyläther nach Friede 1-Crafts der Kondensation mit ß-Chlorpropionylchlorid unterwerfen und die substituierten ß-Chlorpropiophenone mit den entsprechenden basischen Verbindungen umsetzen, was sich noch einfacher gestaltet.But you can also use 2-ethyl-phenylaIkyläther according to Friede 1-Crafts Subject to condensation with ß-Chlorpropionylchlorid and the substituted ß-Chlorpropiophenone Implement with the appropriate basic compounds, which is even easier designed.
Als basische Komponenten können zur Erzielung der beabsichtigeten Wirkung sowohl aliphatische als auch heterocyclische sekundäre Amine verwendet werden, z.B. n-Dibutylanilin, Piperidin, 4-Athylpiperidin, Hexamethylenimin, Morpholin, Pyrrolidin u.a.As basic components can be used to achieve the intended Effect both aliphatic and heterocyclic secondary amines are used, e.g. n-dibutylaniline, piperidine, 4-ethylpiperidine, hexamethyleneimine, morpholine, Pyrrolidine et al.
Die erfindungsgemäßen Verbindungen der allgemeinen Formel (I) stellen weiße, kristalline, geruchlose Verbindan-en dar, die in Wasser und Alkohol gut löslich und als Anästhetika vielfältig verwendbar sind.The compounds of the general formula (I) according to the invention represent white, crystalline, odorless compounds that are readily soluble in water and alcohol and can be used in many ways as anesthetics.
Sie konnen z.B. in Form von Injektionslösungen, Salben, Pudern, Tabletten, Suppositorien und Sprays eingesetzt werden. In diesen Zubereitungen sind sie zur Lokal-, Schleimhaut- und Leitungsanästhesie geeignet.They can e.g. in the form of injection solutions, ointments, powders, tablets, Suppositories and sprays can be used. In these preparations they are used for Local, mucous membrane and conduction anesthesia suitable.
So gelangen beispielsweise 0,25 - Q,5-%ige Lösungen, u.U. mit einem geringen Arterenol- oder Adrenalinzusatz, als Injektionslösungen in der Stomatologie, 0,02 - 0,2-%ige Losungen als Infiltrationsanästhetika, 0,5 - 2-%ige Lösungen in der Periduralanästhesie und 0,1 - 0,5-%ige Lösungen für die Leitungsanästhesie zur Verwendung.For example, 0.25 - Q.5% solutions can be obtained with a low addition of arterenol or adrenaline, as injection solutions in stomatology, 0.02 - 0.2% solutions as infiltration anesthetics, 0.5 - 2% solutions in the epidural anesthesia and 0.1-0.5% solutions for the circuit anesthesia for Use.
Lösungen der erfindungsgemä#en Substanzen sind weiterhin in der Ophthalmologie, so zur oberflächigen Anästhesie der Hornhaut, bei Schieloperationen und den verschiedenen Eingriffen an der Bindehaut geeignet.Solutions of the substances according to the invention are also used in ophthalmology, so for superficial anesthesia of the cornea, for strabismus operations and the various Interventions on the conjunctiva are suitable.
Sie finden Verwendung für Bronchoskopien, Bronchographien, Ösophagoskopien, Gastroskopien, Cystoskopien, endobronchiale und endoösophagale Eingriffe, Fremdkörperentf ernungen usw, Bei der Periduralanästhesie liegt eine besondere Anwendung in der Gynäkologie.They are used for bronchoscopy, bronchography, esophagoscopy, Gastroscopy, cystoscopy, endobronchial and endoesophageal interventions, foreign body removal erungen, etc., The epidural anesthesia has a special application in the Gynecology.
In Kombination mit z.B. Bismutum subgallicum und Oleum pedum tauri werden Suppositorien erhalten, die bei Hämorrhoiden, Anal-Fissuren, Anal-Rhagaden u.a. wirksam sind.In combination with e.g. Bismutum subgallicum and Oleum pedum tauri suppositories are obtained that treat hemorrhoids, anal fissures, anal fissures i.a. are effective.
In Form von Sprays sind die erfindungsgemäßen Substanzen zur Vorbereitung von Eingrifien, insbesondere in der Otologie, Rhinologie und Stomatologie geeignet.The substances according to the invention are in the form of sprays for preparation suitable for interventions, especially in otology, rhinology and stomatology.
Die folgenden Beispiele sollen die Herstellung der neuen Verbindungen der allgemeinen Formel I erläutern sowie deren Eigenschaften charakterisieren, die Erfindung aber in keiner Weise einschränken.The following examples are intended to illustrate the preparation of the new compounds of the general formula I explain and characterize their properties, the In no way limit the invention.
Beispiel 1: 2-Xthylphenol (1 Mol) wird durch halbstündiges Erhitzen mit 1,1 Mol Acetanhydrid und einem Tropfen Schwefelsäure in das Acetat übergeführt.Example 1: 2-Xthylphenol (1 mole) is obtained by heating for half an hour converted into the acetate with 1.1 mol of acetic anhydride and a drop of sulfuric acid.
1 Mol 2-Äthylphenylacetat in 300 g Nitrobenzol oder o-Nitroäthylbenzol wird mit 170 g wasserfreiem Aluminiumchlorid versetzt. Nach 3-stdg. Reaktion bei 500 C wird in Eis/Salzsäure gegossen und Nitrobenzol oder o-Nitroäthylbenzol mit Wasserdampf abgetrieben. Aus dem Rückstand wird 3-Äthyl-4-hydroxy-acetophenon, das als Öl im Gemisch mit Wasser verbleibt und bald erstarrt, gewonnen. 1 Mol dieses wird mit 1,1 Mol Alkylbromid durch 5-stdg. Erhitzen in Gegenwart von 1,1 Mol wasserfreiem Kaliumcarbonat und 150-200 ml Aceton veräthert, worauf 1 Mol des Ethers mit 0,95 Mol Piperidinhydrochlorid und 2,5 Mol Paraformaldehyd in 140 ml Alkohol 5 Std. erhitzt wird. Das Hydrochlorid der Ketobase wird durch Behandeln des Reaktionsgemisches mit Äther abgetrennt und durch Umfällen gereinigt.1 mole of 2-ethylphenyl acetate in 300 g of nitrobenzene or o-nitroethylbenzene 170 g of anhydrous aluminum chloride are added. After 3 hours Reaction at 500 C is poured into ice / hydrochloric acid and nitrobenzene or o-nitroethylbenzene with Water vapor driven off. From the residue is 3-ethyl-4-hydroxy-acetophenone, the Remains as an oil in a mixture with water and soon solidifies, won. 1 mole of this is with 1.1 mol of alkyl bromide by 5 hrs. Heating in the presence of 1.1 moles of anhydrous Potassium carbonate and 150-200 ml of acetone etherified, whereupon 1 mol of the ether with 0.95 Moles of piperidine hydrochloride and 2.5 moles of paraformaldehyde in 140 ml of alcohol for 5 hours will. The keto base hydrochloride is obtained by treating the reaction mixture separated with ether and purified by reprecipitation.
Beispiel 2s 1 Mol Äthylphenol wird mit 1,1 Mol n-Hexylbromid wie in Beispiel 1 veräthert.Example 2s 1 mol of ethylphenol is mixed with 1.1 mol of n-hexyl bromide as in Example 1 etherified.
1 Mol ß-Chlorpropionylchlorid, 1 Mol 2-Äthylphenyi-nhexyläther und 500 ml Schwefelkohlenstoff werden unter Rühren mit 148 g Aluminiumchlorid versetzt. Nach Abklingen der Reaktion wird weitere 60 Minuten zum Sieden erhitzt.1 mol of ß-chloropropionyl chloride, 1 mol of 2-Äthylphenyi-nhexyläther and 500 ml of carbon disulfide are mixed with 148 g of aluminum chloride while stirring. After the reaction has subsided, the mixture is heated to boiling for a further 60 minutes.
Das Reaktionsgemisch wird auf Eis/8alzsäure gegossen, die organische Phase abgetrennt, mit Calciumchlorid getrocknet und das Lösungsmittel versagt.The reaction mixture is poured onto ice / hydrochloric acid, the organic Phase separated, dried with calcium chloride and the solvent fails.
Sodann wird in 500 ml Methanol gelöst und mit 120 g wasserfreiem Kaliumacetat zum Sieden erhitzt. Nach Erkalten werden 3 Mole Piperidin in 500 ml Alkohol zugegeben. Nach Beendigung der Reaktion wird mit Wasser versetzt, angesäuert und mit Äther extrahiert. Mit Natronlauge scheidet sich die Ketobase ab, die in das Hydrochlorid übergeführt wird.It is then dissolved in 500 ml of methanol and mixed with 120 g of anhydrous potassium acetate heated to boiling. After cooling, 3 moles of piperidine in 500 ml of alcohol are added. After the reaction has ended, water is added, the mixture is acidified and ether is added extracted. The keto base separates out with caustic soda, which is converted into the hydrochloride is convicted.
Beispiel 3: ß-Piperidino-3-äthyl-4-alkoxypropiophenon-hydrochloride:
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19681770273 DE1770273A1 (en) | 1968-04-26 | 1968-04-26 | New basic ketones |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19681770273 DE1770273A1 (en) | 1968-04-26 | 1968-04-26 | New basic ketones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1770273A1 true DE1770273A1 (en) | 1972-03-23 |
Family
ID=5700458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19681770273 Pending DE1770273A1 (en) | 1968-04-26 | 1968-04-26 | New basic ketones |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE1770273A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1270705B (en) * | 1962-01-16 | 1968-06-20 | Gen Electric | Electric iron with setting option for operation with two different voltages |
| US6165557A (en) * | 1996-01-04 | 2000-12-26 | Basf Coatings Ag | Solvent-free coating compositions which can be cured with low emissions |
-
1968
- 1968-04-26 DE DE19681770273 patent/DE1770273A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1270705B (en) * | 1962-01-16 | 1968-06-20 | Gen Electric | Electric iron with setting option for operation with two different voltages |
| US6165557A (en) * | 1996-01-04 | 2000-12-26 | Basf Coatings Ag | Solvent-free coating compositions which can be cured with low emissions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH626873A5 (en) | ||
| DE1770273A1 (en) | New basic ketones | |
| DE527714C (en) | Process for the preparation of soluble compounds of oxydiphenyl ethers or oxydiphenyl sulfides and their derivatives | |
| DE1922578C3 (en) | 4,7,10-trioxatrldecane-1,13-dioyibis- (3-carboxy-2,4,6-triiodo-anilide) and its salts, processes for the preparation of these compounds and X-ray contrast media containing these compounds | |
| DE2022858A1 (en) | New basic ketones having local anaesthetic - effect | |
| DE1545672B2 (en) | Dicarboximide derivatives and processes for their preparation | |
| AT133143B (en) | Process for the preparation of readily soluble sodium salts of 4-oxy-3-acylaminobenzolaric acids (1) or their substitution products. | |
| DE839938C (en) | Process for the preparation of new dialkylamides from alkoxy-substituted benzoic acids | |
| DE940828C (en) | Process for the preparation of esters of penicillin with phenols and thiophenols | |
| DE1922606C3 (en) | Alkanedioyl-bis- (3-acylaminomethyl-5-carboxy-2,4,6-triiodo-anilide) and their salts, processes for the preparation of these compounds and X-ray contrast media containing these compounds | |
| DE1570013C (en) | 1,4 Bis (phenoxyacetyi) piperazinden vate and process for their preparation | |
| AT215414B (en) | Process for the preparation of new β-hydroxybutyric acid amide derivatives | |
| DE958844C (en) | Process for the production of ª † -acyl-butyric acids | |
| DE858400C (en) | Process for the preparation of iodinated pyridone derivatives of carboxylic acids | |
| AT216496B (en) | Process for the preparation of new α-substituted glycine derivatives | |
| AT147483B (en) | Process for the preparation of compounds of methyl N-methyltetrahydronicotinate. | |
| AT343139B (en) | PROCESS FOR PRODUCING NEW PHOSPHINYL DERIVATIVES | |
| AT215415B (en) | Process for the preparation of new β-hydroxybutyric acid amide derivatives | |
| AT216497B (en) | Process for the preparation of new β-hydroxybutyric acid amide derivatives | |
| AT33448B (en) | Process for the preparation of aminoalkyl esters. | |
| DE2318043C3 (en) | Bis-square brackets on 4,7-dihydroxycumarinyl- (3) square brackets acetic acid and its pharmacologically acceptable salts as well as processes for their production and pharmaceuticals containing these compounds | |
| AT151657B (en) | Process for the preparation of formaldehyde sodium sulfoxylates from arsenobenzene compounds. | |
| AT120407B (en) | Process for the preparation of esters of derivatives of 4-oxypiperidine. | |
| AT282594B (en) | PROCESS FOR THE PREPARATION OF NEW RACEMIC OR OPTICALLY ACTIVE (1-2'-NITRILOPHENOXY) -2-HYDROXY-3-ISOPROPYLAMINOPROPANE AND ITS SALTS | |
| AT317196B (en) | Process for the preparation of new 1-benzoyloxy-2-lower-alkylaminobenzocycloalkane derivatives |